Sareum enhances SDC-1801 patent protection

Cambridge, UK, 3 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Japan Patent Office has issued a Notice of Allowance for a patent relating to SDC-1801, the Company's lead TYK2/JAK1 kinase inhibitor.

The newly approved Japanese patent, Special Application 2021-543577, safeguards SDC-1801 and its medical applications in treating inflammatory or immune disorders. This follows the earlier approval by the China National Intellectual Property Administration (CNIPA), which issued patent number CN113056456B for the same protections earlier this year. Patent applications in Europe (EP3864009), the US (US2021387981), and other territories are still under review.

The Company expects that the patent will be granted in the near future, subject to certain formalities being completed.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "The recent Notice of Allowance from the Japan Patent Office bolsters our growing confidence in SDC-1801, our lead TYK2/JAK1 kinase inhibitor. Our Phase 1a clinical trial in Australia is progressing well, and this latest patent recognition in Japan supports our intellectual property around this programme."

Further information on our patents can be found on our website at: https://sareum.com/patents/